Orano Med Inaugurates a New Lead-212-Based Radioligand Therapies Production Site
Orano Inaugurates a New Lead-212-Based Radioligand Therapies Production Site Earlier this October, Orano Med, a subsidiary of Orano (ENS Corporate Member), announced the inauguration of its ATLab (Alpha Therapy Laboratory) in Valenciennes, France. It is Europe’s first industrial-scale pharmaceutical facility dedicated to producing lead-212-based radioligand therapies. Lead-212 is increasingly recognised for its role in targeted alpha therapies (TATs),…